In one paragraphArticle in Science signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Mark E RobinsonCenter of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.ORCID 0000-0003-2363-6047 Zhangliang ChengCenter of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.
Kadriye Nehir CosgunCenter of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA.ORCID 0000-0003-4181-744X Ning MaDepartment of Computational and Quantitative Medicine and Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0003-4653-7797 Christian HurtzDivision of Cancer Sciences, Department of Basic Science, Loma Linda University, Loma Linda, CA 92354, USA.ORCID 0000-0001-8346-190X Huimin GengDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-5339-5446 Selina M LugerDivision of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-3364-4366 Elisabeth PaiettaDepartment of Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.
Jianjun ChenDepartment of Computational and Quantitative Medicine and Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0003-3749-2902 Nagarajan VaidehiDepartment of Computational and Quantitative Medicine and Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0001-8100-8132 Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MMetabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MLymphoid-specific high-efficiency beta-catenin protein degradationR01AI192914 · NIAID · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2025 to 2025
$3.1MSYK and ZAP70 kinases in lymphocyte selectionR01AI164692 · NIAID · YALE UNIVERSITY · PI Eric Meffre, Markus Müschen · 2022 to 2026
$3.1MTargeting GSK3B in refractory B-cell malignanciesR01CA282877 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2023 to 2026
$2.4MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MNCI NIH HHS R01 CA157644NCI NIH HHS R01 CA213138NCI NIH HHS R01 CA282877NCI NIH HHS R35 CA197628NCI NIH HHS U10 CA180820NIAID NIH HHS R01 AI164692NIAID NIH HHS R01 AI192914
6 · The paper itselfAbstract
CD25 is a subunit of the interleukin-2 (IL-2) receptor on T cells and natural killer (NK) cells. Acute leukemias with oncogenic tyrosine kinases often include CD25
Indexed as
Feedback, PhysiologicalInterleukin-2 Receptor alpha SubunitLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase C-deltaSignal TransductionAnimalsHumansMiceNF-kappa BPhosphorylationProtein Tyrosine Phosphatase, Non-Receptor Type 6IL2RA protein, humanInterleukin-2 Receptor alpha SubunitNF-kappa BProtein Kinase C-deltaProtein Tyrosine Phosphatase, Non-Receptor Type 6
Identifiers
PMID41666265
PMCPMC12924454
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390